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1. Introduction
Oral way is the most important route of drug administration for obtaining systemic pharma‐
cological effects. In this route, the solid dosage form specially tablets, are the first choice of
patient because of their some special advantages like easy administration by the patient, unit
dosage form with greatest dose precision and least content variability, lower cost and temper
proof nature [1]. Due to unfavourable physical and mechanical properties and poor aqueous
solubility of some drugs, their formulation process becomes problematic. Crystallization is the
main process in the pharmaceutical industry for particle formation and may be defined as the
process in which a solid compound precipitates from a saturated solution in the form of crystals
[2, 3].Most active pharmaceutical ingredients are manufactured in a crystalline shape for their
chemical stability during transportation, packaging and storage. Many factors including
thermodynamic (e.g., solubility, solid-liquid interfacial tension, solvent activity, temperature,
etc.), kinetic (e.g., supersaturation, molecular mobility, meta-stable zone width) and molecular
recognition (hydrogen bonds, non-covalent bonds, molecular networks) influence the rate and
mechanisms by which crystals are formed from liquid solutions [3, 4]. The driving force for
crystallization is supersaturation. Supersaturation can be generated by increasing the solute
concentration (solvent evaporation) or decreasing the solute solubility (e.g., temperature
change, anti-solvent addition, pH change, salting-out) [5]. The next step is the formation of
macroscopic crystals from stable nuclei, called crystal growth. This step is controlled by
internal (crystal structure) and external factors (temperature, impurities, supersaturation,
solvent type) and determines the particle morphology [6].
The size and shape are very important parameters that influence the separation process which
will in turn have an effect on the yield and quality of the resulting fractions during the
crystallization process [7]. Particle orientation was influenced by crystal habit, therefore can
modify the flowability, packing, compatibility, syringability, physical stability and dissolution
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profile of a drug molecule. For example, it has been showed that symmetrically shaped crystals
of ibuprofen have better compaction and flow properties than needle shaped crystals [8, 9]. It
seems that optimization of crystal properties is an alternative method for modifying the
dissolution properties of drugs and therefore their bioavailability [10, 11].
Poor physical and mechanical properties of drug particles have been traditionally covered by
various granulation methods. Enlargement of particle size is an important procedure during
manufacturing of tablets [12]. There are different techniques for enlargement of particle size
such as wet granulation, dry granulation, extrusion spheronization and spherical crystalliza‐
tion methods [13]. These techniques have important role in modifying primary and secondary
properties of pharmaceutical substances. Kawahima and Capes (during the 1970 decade)
suggested enlargement of particles size during the crystallization process. According to their
report, controlling the crystal’s agglomeration leads to spherical agglomerates with accorded
properties [14].
In 1986, Kawashima applied the spherical crystallization method for size enlargement of drugs
in the pharmaceutical field. Spherical crystallization defined by him as “An agglomeration
process that transforms crystalline drugs directly into a compacted spherical form for improv‐
ing the flowability, solubility and compactability” [14, 15]. Spherical agglomeration (SA) and
emulsion solvent diffusion (ESD) are two major techniques for spherical crystallization. In fact
the ammonia diffusion systems (ADS) and crystallo-co-agglomeration (CCA) are extended
forms of these methods [16]. Spherical agglomeration consists of precipitating fine crystals of
the drug substance and then aggregating them using a wetting agent (should be a non-miscible
liquid).In the emulsion solvent diffusion technique, the continuous phase is a non-miscible
iquid with drug. Indeed in this method, a quasi-emulsion is formed by droplets of solvent
containing the drug and then crystallization occurs inside the droplets because of the counter
diffusion of the solvents through the droplets [15]. Under controlled conditions, such as solvent
composition, temperature regulation, supersaturation generation, or mixing speed, crystal‐
lized particles are able to agglomerate into the spherical dense agglomerates simultaneously.
2. Spherical crystallization
Good flowability, mechanical strength and compressibility are the main requirements for
commercial production of a particulate solid into the tablet dosage form [14]. Nowadays, great
advancements are accessible by powder technology, and various studies are made to produce
primary and secondary particles of pharmaceutical substances for different applications. The
spherical crystallization is a particle size enlargement method that applies crystallization and
agglomeration using bridging liquid [17]. Indeed, this method is a particle design technique
that crystallization and agglomeration can be performed simultaneously in one step for
transforming crystals directly into the compacted spherical forms [18, 19]. By using this
method, direct tabletting of drug instead of further processing like mixing, granulation, sieving
and drying is possible [15, 16, 19].This technique is capable of subsequent processes such as
separation, filtration and drying more efficiently and is able to have an effect on the secondary
properties of the crystals such as flowability, compressibility and wettability. Using this
technique, the precipitated crystals can be agglomerated during the final synthesis step into
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more or less spherical particles with sizes between 300 and 500 mm without any binders.
Spherical crystallization has been considered as a very effective method in improving the
dissolution profile of some poorly water soluble drugs [13, 14, 19].
Mechanical properties of the spherical agglomerates like packability, flowability, compressi‐
bility, mechanical strength and elastic recovery are very important for the handling and
bioavailability of the particles [20]. Stronger bonding occurs during compression of agglom‐
erated crystals compared to single crystals and greater tensile strength is obtained from
agglomerated crystals compared to single crystals. It was demonstrated that the spherical
agglomerates are more compressible and suitable for preparing compressed dosage forms than
conventional crystals. The stronger bond forces formed from agglomerated crystals lead to
greater plastic deformation and higher tensile strength compared to those created from single
crystals [21]. Jbilou et al. reported that the improvement of compression ability of the agglom‐
erated crystals of ibuprofen compared to marketed single crystals (in spite of high crystallinity)
is related to the isotropic texture of the agglomerate [22].
2.1. Principle of spherical crystallization
The saturated solution of the drug in a good solvent is poured into a poor solvent. A third
solvent known the bridging liquid is added in small amounts to wet the crystal surface and
promote the formation of liquid bridges between the drug crystals for forming spherical
agglomerates [23]. In this process the poor and good solvents should be freely miscible and
the affinity between the solvents must be stronger than the affinity between drug and the good
solvent. Furthermore, the bridging liquid should not be miscible with the poor solvent and
should preferentially wet the precipitated crystals [15]. Advantages and disadvantages of
spherical crystallization method are summarized in Table 1.
Advantages Disadvantages
Physicochemical properties of pharmaceutical crystals are
mainly improved for pharmaceutical process i.e. milling,
mixing and tabletting by using this technique [24].
Selection of suitable solvents is a tedious process [2].
Use of this technique leads to conversion of crystalline
forms of a drug into polymorphic form that may have
better bioavailability [23].
Optimization of processing parameters (temperature,
agitation) is difficult [16].
This technique could enable subsequent processes such as
separation, filtration, drying, etc. to be carried out more
efficiently [15].
Preparation of microsponges, microspheres and
nanospheres, microballoons, nanoparticles and micro
pellets as novel particulate drug delivery system is
possible by it [25].
It can be used for masking of the bitter taste of drug [15].
Table 1. Advantages and disadvantages of spherical crystallization
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2.2. Main steps involved in the growth of agglomeration
Bermer and Zuider Wag classified the growth of agglomeration in four steps: Flocculation
zone, zero growth zone, fast growth zone and constant size zone [26].
2.2.1. Flocculation zone
The bridging liquid is adsorbed on the surface of crystals and links the particles by forming
bridge between them [15, 26].
2.2.2. Zero growth zone
In this zone, loose floccules are converted into the tightly packed pellets. The entrapped fluid
is squeezed out onto the surface of the small floccules. The driving force for these conversions
is governed by the agitation of the slurry, pellet-pellet and pellet-stirrer collision [27].
The rate limiting step in agglomeration growth process occurs in zero growth zones when
bridging liquid is squeezed out of the pores as the initial floccules are transformed into small
agglomerates.
2.2.3. Fast growth zone
When sufficient bridging liquid has squeezed out of the surface of the small agglomerates, the
fast growth zone is observed. Coalescence is the process in which the large size particle is
formed following random collision of well-formed nucleus. For successful collision process,
slightly excess surface moisture of nucleus is required [27, 28].
2.2.4. Constant size zone
This zone involves stopping of agglomeration growth. In this zone, even a slight decrease in
size of agglomerates may be observed probably due to attrition, breakage and shatter. Four
zones for agglomeration growth are illustrated in Figure 1 [26-28].
Figure 1. Four steps for agglomeration growth: a) flocculation zone, b) zero growth zone, c) fast growth zone, d) con‐
stant size zone
3. Spherical agglomeration technique
There are three main stages for spherical agglomeration method. The first stage is the choice
of the crystallization method to precipitate crystals from solution.  The thermal,  physico‐
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chemical or chemical methods may be used in this stage. The second step is the selection
of  the  wetting  agent  that  should  be  immiscible  with  the  solvent  of  the  crystallization
process.  At  the end stage,  the hardening of  the agglomerates  is  performed.  Agglomera‐
tion  may occur  as  a  consequence  of  the  coalescence  of  agglomerates  with  the  liberated
bridging liquid [29].
Spherical crystallization has been employed for several high dose drugs with poor compres‐
sibility and poor water solubility [24].
Spherical  agglomeration  is  a  valuable  technique  in  the  formulation  of  microspheres,
microsponges,  nanospheres,  microballoons  and  nanoparticles  as  novel  drug  delivery
systems [30]. Spherical agglomeration is also employed in processes such as granulation,
balling,  pelletization,  tabletting,  compaction,  flocking and sintering in  order  to  produce,
e.g., nuclear fuel pellets, ceramic powders, carbon blacks, catalysts, commercial fertilizers,
pesticides and pharmaceutical products [31]. The main parameters in spherical agglomera‐
tion  are  the  choice  of  the  solvent  system,  amount  and type  of  the  bridging  liquid,  the
presence of  additives,  initial  particle  size,  solubility,  the  agitation rate  and temperature.
These  parameters  influence not  only  the  productivity  but  also  the  micrometrics  proper‐
ties such as particle size distribution, morphology and strength of the product [17]. Figure
2 shows the principle of spherical agglomeration.
Figure 2. Principle of spherical agglomeration
3.1. Solvent system
Polarity of the solvent and its interactions with hydrophobic phases of the growing crystals
have an influence on shape, surface irregularity and roundness of the crystals agglomer‐
ate [32]. Commonly three types of solvents are used in spherical agglomeration [27]: a) A
perfect solvent for the drug, b) anti-solvent and c) bridging liquid that should be added
for promoting the formation of agglomerates. Bridging liquid not only has wetting property
but also acts as an interparticle binder promoting agglomeration. The bridging liquid should
not be miscible with the anti-solvent. Meanwhile, anti-solvent and solvent systems should
not be miscible and the affinity between them must be stronger than those between drug
and solvent [15,  17,  25].  The solvent system and its composition are usually selected by
trial and error. Examples of solvent systems in preparing spherical agglomeration of some
drugs are given in Table 2.  Also the common solvent system in spherical  crystallization
method is shown in Figure 3.
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Drug
Solvent system
Technique References
Good solvent Poor solvent Bridging liquid
Flubiprofen Acetone Water Hexane SA [33]
Salicylic acid Ethanol Water Chloroform SA [34]
Aspirin Acid buffer, Methanol, Chloroform SA [35]
Fenbufen THF Water Isopropyl acetate SA [36]
Nabumetone Ethanol Water Cyclohexane SA [37]
Naproxen Acetone-ethanol Water Chloroform SA [38]
Roxythromycin Methanol Water Choroform SA [39]
Mebendazole Acetone Water Hexan,Octanol,Dichloromethane SA [40]
Valsartan Acetone Water Choroform SA [41]
Celocoxib Acetone Water Chloroform SA [42]
Ascorbic acid Water Ethyl acetate Ethyl acetate SA,ESD [43]
Aspartic acid Methanol Water - SA [44]
Ibuprofen Ethanol Water Ethanol SA [22]
Ibuprofen-
Paracetamol Dichloromethane Water Dichloromethane CCA [45]
Benzoic acid Ethanol Water Chloroform SA [46]
Aceclofenac Acetone Water Dichloromethane SA [47]
Indomethacin Dimethylformamide Water Chloroform SA [48]
Indomethacin
Mepirizole Ethyl acetate Water Ethyl acetate CCA [49]
Ibuprofen-Talc Dichloromethane Water Dichloromethane CCA [50]
Glibenclamide Dichloromethane Water Chloroform SA [51]
Tranilast Acetone Water Dichloromethane SA [52]
Aminophylline Ethanol Water Chloroform SA [53]
Bromohexin Hcl Dichloromethane Water Dichloromethane CCA [54]
Ketoprofen Isopropyl acetate Water Choroform SA [55]
Propiphenazone Ethyl alcohol Water Isopropyl acetate SA [14]
Acetylsalicyclic
acid Ethanol Water Carbon tetrachloride SA [56]
Ketoprofen-talc Dichloromethane Water Dichloromethane CCA [57]
Table 2. Solvent systemsin preparing spherical agglomeration of drugs
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Figure 3. Common solvent system in spherical crystallization method
3.2. Bridging liquid
The amount of bridging liquid is a critical factor in the spherical crystallization method.There
are some studies about the enlargement of agglomerates by increasing the amount of bridging
liquid [58]. Generally, increasing amount of the bridging liquid leads to an increase in
agglomerate size [59]. According to a research, addition of a smaller amount of bridging liquid
produced larger particles of acebutolol (up to 1,000mm) and vice versa a greater amount of
bridging liquid formed smaller particles (around 600mm) [25, 60]. The rate of addition of
bridging liquid in the system also influences the spherical nature of the crystals [32, 61].The
strength of the bridges not only depends on the interfacial tension between the bridging liquid
and the medium but also depends on the rheology of the bridging liquid [32].
There are very limited reports on the systematic selection of the solvent system and bridging
liquid for spherical crystallization. Most articles do not address the reasoning behind their
solvent selection. Chow and Leung proposed some rules for selection of solvent system and
bridging liquid [26]: For water soluble compounds, an organic solvent that is miscible with
water  is  employed as the poor solvent  and salt  solutions in high concentration without
common ions can be applied as  the bridging liquid.  In the case of  compounds that  are
soluble in one or more organic solvents, water is used as the poor solvent and a water-
immiscible organic solvent as the bridging liquid. For compounds that are only soluble in
water-miscible  organic  solvents,  a  saturated  aqueous  solution  of  the  compound and an
organic  solvent  could  be  used  as  poor  and  bridging  solvents  respectively.  Finally  for
materials with insufficient solubility in water or any organic solvent,  a water-immiscible
organic solvent employ as the poor solvent and salt solutions in high concentration without
common ions as the bridging liquid. In the latter case because of insufficient solubility of
drug powder in bridging liquids, presence of a binding agent such as PVP 40000 or PEG
10000 is necessary for agglomeration [25].
Chloroform has been employed as a bridging liquid in the preparation of some spherical crystal
drugs such as: salicylic acid, Aspirin, Roxithromycin, Trimethoprim, Tranilast anhydrate and
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Tranilast monohydrate. Isopropyl acetate has been used in the spherical crystal preparation
of Propyphenazone, Acebutolol hydrochloride, Tolbutamide and Fenbufen for this mean.
Because the strength of liquid bridges is proportional to the interfacial tension between the
bridging liquid and the solid, surfactants are not usually used as bridging liquid [31]. Figure
4 shows the mechanism of liquid bridge formation in spherical agglomeration.
Figure 4. The mechanism of liquid bridge formation in spherical agglomeration
3.3. The presence of additives
The presence of additives such as polymeric material and surface active agents are able to
influence molecular aggregation during the crystallization process [40]. The viscosity of the
medium and surface tension are reduced by surfactants that in which affect the nucleation
process. The existence of these additives in the spherical agglomeration process may also
reduce the processing time and improves the bioavailability and micrometric properties of the
drug.
Crystallization is inhibited by some of the polymers such as methylcellulose, hydroxypropyl
methyl cellulose (HPMC) andpolyvinyl pyrrolidone (PVP). Among these, PVP has been found
to be the most effective crystallization inhibitor. These anti-nucleant polymers are incompat‐
ible with the host molecules of the growing crystals surface. Then their incorporation into the
lattice alters growth characteristics of the host molecules [62].
3.4. Particle size
Particle size distributions of the drugs and their excipients can exert major effects on the mixing
process and therefore on possible segregation in the mixed materials. The particle size
distribution in powder material can also influence the flowability and bioavailability of certain
active drugs. When the concentration of the organic phase is close to the saturation of the liquid
phase, the particles have soft (gel like) and sticky structure. These sticky structures during the
process lead to particles sticking to the impeller and crystallizer wall. Indeed, the gel like
structure is achieved when the mass transfer from the organic phase to aqueous phase is too
slow. Then the life-time of the emulsion is much higher leading to an enhancement in coales‐
cence frequency of the droplets [61].
3.5. Solubility of drug
As mentioned earlier, the solvent system for spherical crystallization includes a poor solvent,
a good solvent for the drug and bridging liquid. Venkadari Rammohan Gupta described a
method for the selection of solvents that is dictated by the solubility characteristic of the drug
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[42].Physical state of a drug product (whether microagglomerate or irregular macro-agglom‐
erates or a paste of drug substance) may be controlled by selecting of proper solvent propor‐
tions. The solvent proportions is determined by performing solubility tests and then
constructing triangular phase diagram for defining the region of mutual immiscibility using
ternary diagram [63].
3.6. Mode and intensity of agitation
Similar to the consolidation in granulation process, in the spherical agglomeration process, the
spherical shape particles are formed due to mechanical forces of the agitation over a long
period of time. In several reports, effects of the agitation rate were reported, and it is one of
the main parameters to determine average diameter of the agglomerated crystals [64]. Mode
and intensity of agitation in conjugation with the amount of bridging liquid determines the
rate of agglomerate formation and their ultimate size. High speed agitation is required for the
dispersion of the bridging liquid throughout the system. Altering of the agitation pattern leads
to change in force acting on the agglomerate and therefore has an effect on the shape of the
agglomerate.
Some drugs require low agitation rate for crystallization, whereas some need elevated rate.
Blandin et al. stated that a higher stirring rate leads to obtaining less porous and more resistant
agglomerates [24].
The rate of crystallization in the system determines nature of the agitation speed. If the rate of
drug crystallization was high, then the elevated agitation speed is required for agglomeration.
The used blade for agitation has important role on the shape of agglomerates. Commonly
screw-type agitator with four flat blades is used for maintaining the shape. The sharper blades
will cut the agglomerates and irregular agglomerates will be formed [65]. By increasing
agitation rate, the shear force of the system increases and the outcome is more consolidated
agglomerates. By applying a rate above the optimum stirring rate, and due to an increase in
disruptive forces, the agglomeration process becomes less efficient [66, 67].
Maghsoodi et al. showed that increase of the agitation time before adding the bridging liquid
leads to bigger and more elongated crystals. According to their report, needle-like particles
are more difficult to pack than isotropic particles in this situation. They also changed the
stirring time after the addition of bridging liquid. Their results showed that the spherical shape
of the agglomerates does not appear immediately but develops gradually [68].
3.7. Temperature of the system
Temperature has a major influence on the shape, size and texture of the agglomerates. The
effect of temperature on spherical crystallization is maybe due to its effect on the drug solubility
[69].Kawashima et al. [1984] tested the temperature influence on the spherical agglomeration
of salicylic acid in a tertiary system (water-ethanol-chloroform). By increasing the temperature,
the solubility of drugs is increased and then a decrease in the recovery of the crystals is
observed. At lower temperature, recovery of the crystals increases and the constituent crystal
size and the solubility of chloroform in the solvent mixture diminishes [70]. Furthermore,
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temperature has an effect on the crystallization stages such as nucleation, crystallization and
agglomeration of crystals. According to Kawashima and Capes [1984], spherical agglomera‐
tion follows first order kinetics with respect to increasing number of agglomerates with time.
The bulk density of the agglomerates also decreases by increasing the crystallization temper‐
ature [70].
3.8. Residence time
The residence time that agglomerates remain suspended in reaction mixture influences the
size, shape and strength of agglomerates. During long residence time because of the solubili‐
zation of the agglomerates by the bridging liquid, the agglomerates break down into smaller
crystals and the size of agglomerated particles decreases [32]. Then the optimization of
residence time for the agglomeration of recrystallized crystals is necessary. Below the opti‐
mized residence time, incomplete effusion of good solvent and bridging liquid from the
formed droplets in the dispersion medium leads to the incomplete agglomeration [32].
4. Quasi-emulsion solvent diffusion
In this process, the quasi-emulsion of drug solution in good solvent with a poor solvent (non-
solvent) is formed. Due to counter diffusion of good solvent and poor solvent, crystallization
of the drug occurs. Stabilization of emulsion by proper polymer is required in this method. In
fact, the drug and polymer are co-precipitated in order to form drug crystals according to the
polymer properties. Residual good solvent in droplets acts as a bridging liquid to agglomerate
the generated crystals [8, 27].
Figure 5. The mechanism of emulsion solvent diffusion method: a) emulsion formation, b) coalescence of emulsion
droplet,c) diffusion of good solvent to outer phase and poor solvent into of the droplet, d) growth of crystal shell and
final agglomerates
Patil and Sahoo prepared the spherical agglomerates of glibenclamide by emulsion solvent
diffusion method. They used methanol, chloroform and water as good solvent, bridging liquid
and poor solvent respectively. According to their results, particle size, flowability, compacti‐
bility and packability of plane and agglomerates with additives except with polyvinyl
pyrrolidone were preferably improved for direct tabletting compared with raw crystals of
glibenclamide. Their results also showed significant improvement in solubility and dissolution
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rate of plane and agglomerates with additives except with polyvinyl pyrrolidone, compared
with the raw crystals of the drug. The authors believe that improved properties of spherically
agglomerated crystals is due to their large and spherical shape and enhanced fragmentation
during compaction that is supported by increased tensile strength and less elastic recovery of
its compact [28]. The mechanism of emulsion solvent diffusion method is shown in Figure 5.
5. Ammonia diffusion method
Ammonia diffusion components consist of ammonia water as a good solvent and also bridging
solvent, poor solvent and hydrocarbon or halogenated hydrocarbon (acetone). The hydrocar‐
bon is miscible with the system, and it should reduce the miscibility of the ammonia water
with poor solvent. The diffusion process across the droplet consists of moving poor solvent
inside and ammonia out of the droplet. Then the drug crystals precipitatein ammonia water
slowly and agglomerates are grown [8, 27].Figure 6 shows this process.
Figure 6. Ammonia diffusion method for preparation of spherical crystallization: a) movement of poor solvent into the
droplet, b) movement of ammonia out of the droplet, c) the drug crystals precipitate in ammonia water slowly and
agglomerates are grown
6. Crystallo-Co-Agglomeration (CCA) technique
Due to the hydrophobic nature of most excipients, incorporation of them in the formed
agglomerates using organic bridging liquid is complicated [71, 72]. Then spherical agglomer‐
ation could not be employed for low-dose or poorly compressible materials. Crystallo-co-
agglomeration technique is one of the novel particles designing technique (developed by
Kadam et al) that could be able to overcome the mentioned limitation of spherical crystalliza‐
tion [30].This process includes continuous stirring of drug and excipients in liquid medium.
The continuous stirring is necessary for loading of the drug consistently in the agglomerates.
In expansion concept, crystallo-co-agglomeration technique involves simultaneous crystalli‐
zation and agglomeration of drug substance with or without excipients from good solvent and/
or bridging liquid by the addition of a poor solvent. The formed crystal of drug has minuscular
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form and therefore the drug dissolution and bioavailability are improved by using this method
[73, 74]. Sometimes bridging liquid also serves as a good solvent. To overcome drug loss due
to co-solvency, the good solvent should be volatile and immiscible with poor solvent [74].
Bridging liquid can affect on the rate of agglomeration and also on the strength of the agglom‐
erates. Smaller amount of the bridging liquid leads to fine particles whereas larger amount
produces coarse particles. When the stirring rate is increased, the agglomeration will be
reduced (because of increasing disruptive forces). Porosity diminishes by increasing concen‐
tration of the solid [66].
Commonly the crystallo-co-agglomeration method can be performed in two ways: solvent
change method and alternate method [75]. In solvent change method, crystallo-co-agglomer‐
ates can be obtained by the crystallization as well as the agglomeration. One or more drugs
simultaneously crystallize and agglomerate from the system containing good solvent and
bridging liquid by the addition of a poor solvent. In the alternate method, the crystallization
of drug is performed from a system containing good solvent and bridging liquid and then its
simultaneous agglomeration is done with an insoluble diluent or a drug by the addition of a
poor solvent. Figure 7 shows the steps involved in crystallo-co-agglomeration technique [76].
Figure 7. Steps involved in crystallo-co-agglomeration technique
6.1. The effect of various factors on crystallo-co-agglomeration process
Crystallo-co-agglomeration technique depends on numerous factors such as the formulation
and process variables which have an effect on the processes of crystallization and agglomer‐
ation. The selection of diluent, solvent system, internal phase, amount and type of polymers
will have an influence on the final agglomerates [75].
Excipients and polymers play a key role in the preparation of crystallo-co-agglomerates, an
excellent alternative to wet granulation process to prepare particles for direct compression
[77].The difference in the physicochemical properties of the drug molecules and the excipient
is the main factor in the selection of a solvent system for the crystallo-co-agglomeration
technique. Various polymers like hydroxy propyl methylcellulose (HPMC), poly ethylene
glycol (PEG), ethyl cellulose (EC) and poly vinyl pyrrolidone (PVP) may be used to improve
poor compressibility and handling qualities of pure drugs by crystallo-co-agglomeration
technique [75]. The micromeritic and drug release properties of the agglomerates are improved
as well. About low dose drugs, diluents are applied for the enlargement of size in the crystal-
co-agglomeration technique. Diluents should be inert and inexpensive. They should also be
insoluble in aqueous phase so that the drug loss through the continuous or external phase be
avoided [74].
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In preparation of directly compressible agglomerates, excipients should have affinity toward
the bridging liquid. Talc is a hydrophobic excipient and has preferential wetting with bridging
liquid therefore is a suitable excipients for incorporation in the crystallo-co-agglomeration
process [30, 71, 74].
6.2. Advantages of crystallo-co-agglomerates
Agglomerates which are prepared using crystallo-co-agglomeration technique have numerous
advantages compared to other spherical agglomeration methods. Excellent flow properties,
large surface area and less chances of dose dumping from final crystals are some of these
advantages. Large surface area leads to uniform distribution of the drug through gastro-
intestinal tract and therefore better absorption and bioavailability is achieved and the toxicity
is also reduced.
Unlike SA, CCA is utilizable for size enlargement of all, low dose, high dose, single, two, or
more drugs in combination with or without diluent [78].
Furthermore, the single step generation of agglomerate, less processing cost, less number of
unit operations and simplicity of the process adapted it to an economic method. In fact,
simplicity and capability to generate spherical agglomerates in a single step are the reasons
for the unique place of crystallo-co-agglomerates technique in the oral drug delivery route. By
crystallo-co-agglomerates technique and proper selection of suitable excipients and polymers,
modified release of drug substances from drug-loaded agglomerates is achievable [30, 71, 74].
It is also possible to create placebo drugs by producing agglomerates of plain excipients (talc
agglomerates) [74].
7. Conclusion
Spherical crystallization is the novel particle design technique, in that crystallization and
agglomeration may be carried out simultaneously in one step and could be able to transform
the fine crystals into a spherical shape directly. In consequence of these modifications, certain
micrometric properties may also be modified. Then this technique is an efficient method in the
optimization of crystal properties for modifying the required micrometric and dissolution
properties of the drugs. In this method, agglomerates with higher bulk density, better flowa‐
bility and compactibility will be obtained. Then the spherical crystallization can be applied for
manufacturing spherical crystals of poorly soluble drugs in order to improve their flowability
and compactibility properties. This technique also is helpful in improving wettability,
bioavailability and dissolution rate of these types of drugs. An optimized spherical crystalli‐
zation process, concerning the form of the agglomerates and reproducibility of the product,
can be applied as an attractive approach for direct tabletting. The final tablet dosage form
prepared using spherical crystallization technique exhibits improvements in strength,
hardness, friability, disintegration profile and dissolution rate compared to those prepared
using granulation method. As a noticeable point, proper selection of solvent, bridging liquid
and diluents has an influence on the release, dissolution, absorption and bioavailability of the
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drug substance and reduce toxicity as well. Agglomerates prepared by crystallo-co-agglom‐
eration technique have numerous advantages over the spherical agglomerates. Spherical
agglomeration could not be employed for low-dose or poorly compressible materials due to
hydrophobic nature of the most excipients. In crystallo-co-agglomeration process, designing
of agglomerates containing two drugs or a low-dose or poorly compressible drug in combi‐
nation with diluents is possible. On the whole, spherical crystallization technique seems to be
promising technique in which the drug crystals are changed by applying different solvents for
obtaining direct compressible spherical agglomerates. This leads to save money and time in
tablet making processes. If it is able to scale up, the direct compression of poorly compressible
drugs will be feasible. Other agglomeration techniques are still less economical than direct
compression tabletting. As an important point, in this process the residues of organic solvent
after the formation of agglomerates should be monitored.
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